人类疱疹病毒6型病毒血症影响异基因造血干细胞移植后T细胞免疫重建
该回顾性分析纳入273例2004至2014年间首次接受异基因造血干细胞移植的儿童患者,每周以PCR筛查血浆HHV6,发现79例(29%)出现HHV6病毒血症,中位发生时间为移植后19天。仅HHV6病毒载量极高(>10^5 copies/mL)的患者自移植后约6个月起CD4+和CD8+ T细胞重建受损,而接受抗病毒治疗的患者T细胞重建改善。
要点
- 273例儿童移植患者中79例(29%)出现HHV6病毒血症,中位时间为移植后19天。
- 仅HHV6病毒载量>10^5 copies/mL者自移植后约6个月起CD4+和CD8+重建受损。
- 接受抗病毒治疗的患者T细胞重建改善(HR 1.572,95%CI 1.463-1.690,P<.001)。
核心结论
- HHV6病毒血症影响移植后晚期而非早期T细胞免疫重建,仅病毒载量极高(>10^5 copies/mL)者CD4+和CD8+重建受损。
研究设计与样本
- 回顾性时间依赖性分析,纳入273例2004至2014年间首次接受异基因造血干细胞移植的儿童患者(0.1-22.7岁),中位随访58个月。
- 每周以聚合酶链反应筛查血浆HHV6,每两周检测CD3/CD4/CD8 T细胞至12周,之后每月检测。
- 采用Cox比例风险模型,以免疫重建和HHV6为时间依赖变量,协变量包括预处理中的血清治疗、移植物来源、移植物抗宿主病、年龄及其他病毒(EB病毒、巨细胞病毒、腺病毒)。
主要发现
- 79例(29%)出现HHV6病毒血症,中位发生时间为移植后19天。
- 仅HHV6病毒载量>10^5 copies/mL的患者与无HHV6者相比,自移植后约6个月起CD4+重建受损(HR 0.913,95%CI 0.892-0.934,P<.001)。
- 仅HHV6病毒载量>10^5 copies/mL的患者与无HHV6者相比,自移植后约6个月起CD8+重建受损(HR 0.912,95%CI 0.891-0.933,P<.001)。
- 尤其初始CD4+免疫重建受影响(P=.028),而效应记忆CD4+免疫重建未受影响(P=.33)。
- 接受抗病毒治疗的患者T细胞重建改善(HR 1.572,95%CI 1.463-1.690,P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human herpesvirus 6 (HHV6) viremia is a common cause of morbidity following allogeneic hematopoietic cell transplantation (HCT). We previously associated T-cell reconstitution with HHV6 viremia. Here, we investigated whether HHV6 viremia affects T-cell reconstitution after HCT in a time-dependent retrospective analysis. We included 273 pediatric patients (0.1-22.7 years; median follow-up, 58 months) receiving a first HCT between 2004 and 2014. HHV6 was screened weekly in plasma via polymerase chain reaction and occurred in 79 patients (29%) at a median time of 19 days after transplant. Main outcome of interest was immune reconstitution (IR) (CD3/CD4/CD8 T cells), measured biweekly until 12 weeks and monthly thereafter. Cox proportional-hazard models were used with IR and HHV6 as time-dependent variables in multivariate analysis with serotherapy in conditioning, graft source, graft-versus-host disease, age, and other viruses (Epstein-Barr virus, cytomegalovirus, and adenovirus) as covariates. Only patients with very high HHV6 viremia (>105 copies/mL) showed hampered CD4+ (hazard ratio [HR], 0.913; 95% confidence interval [CI], 0.892-0.934; P < .001) and CD8+ (HR, 0.912; 95% CI, 0.891-0.933; P < .001) reconstitution in comparison with patients without HHV6, from ∼6 months after HCT. Especially naïve CD4+ IR was affected (P = .028) but not effector memory CD4+ IR (P = .33). Interestingly, T-cell reconstitution was improved in patients treated with antivirals (HR, 1.572; 95% CI, 1.463-1.690; P < .001). These findings suggest that HHV6 viremia affects late but not early T-cell reconstitution.
引用
- de Koning C, Admiraal R, Nierkens S, et al. Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2018. PMID: 29487057. doi:10.1182/bloodadvances.2017012724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。